Cisplatin (CDDP) is a primary agent for the treatment of head and neck squamous cell cancers (HNSCC). During the previous funding period, our group has established that HNSCC cells resistant to CDDP are characterized by high expression of Bcl-xL and wild type p53. Based upon our data, we hypothesize that agents designed to inhibit Bcl-xL or activate p53 function can be highly effective strategies for the treatment of CDDP-resistant HNSCC. To date, we have evaluated a small-molecule inhibitor of Bcl-xL ((-)-gossypol) as a potential novel therapeutic agent for the treatment of HNSCC. Our in vitro and in vivo studies have formed the scientific basis for a future clinical trial of (-)-gossypol in collaboration with Ascenta Therapeutics and the National Cancer Institute. In this new SPORE project, we propose to test a novel therapeutic strategy to target CDDP-resistant HNSCC cells with wild-type p53 status using a potent and specific smallmolecule inhibitor of the MDM2-p53 interaction. In HNSCC cells with wild type p53, the function of p53 is effectively inhibited by its endogenous cellular inhibitor, the MDM2 (or HDM2) protein. MDM2 is transcriptionally activated by p53 and in turn, inhibits p53 activity through multiple mechanisms mediated by direct binding to p53. MDM2 thus functions as a potent and highly effective endogenous inhibitor of p53. We hypothesize that blocking of the interaction between MDM2 and p53 using a potent small-molecule inhibitor can effectively reactivate p53 function in HNSCC cells with wild type p53, which will lead to cell cycle arrest and apoptosis. Design and development of non-peptide, drug-like, small molecule inhibitors to target the MDM2-p53 interaction is an exciting and new therapeutic strategy for the treatment of CDDPresistant HNSCC with wild type p53. Based upon the high-resolution crystal structure of MDM2 in complex with the p53 peptide, we have designed a class of highly potent, non-peptide, small-molecule inhibitors of the MDM2-p53 interaction using an effective structure-based strategy. The most potent small-molecule nhibitor has a Ki value of 2 nM binding to MDM2 protein, 1000-times more potent than the natural p53 peptide. Using a potent lead compound (MI-63) and its inactive control analogue, we have already demonstrated that MI-63 is highly effective in inhibition of cell growth and induction of cell death in HNSCC cancer cell lines with wild-type p53 and displays an excellent selectivity over HNSCC cancer cell lines with mutated p53 status. Moreover, using an isogenic cell line transfected with Bcl-xL protein, we also show that overexpression of Bcl-xL has no effect upon the activity of potent MDM2 inhibitors, in contrast to CDDP. Based upon our preliminary results, we hypothesize that a potent and specific small-molecule inhibitor of the MDM2-p53 will be developed as a new and highly effective therapy for the treatment of HNSCC, either as a single agent or in combination with other therapies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Wolf, Gregory T; Bellile, Emily; Eisbruch, Avraham et al. (2017) Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg 143:355-366
Getz, Kayla R; Rozek, Laura S; Peterson, Lisa A et al. (2017) Family history of cancer and head and neck cancer survival. Laryngoscope 127:1816-1820
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2017) Individualized outcome prognostication for patients with laryngeal cancer. Cancer :
Kim, Hong Sun; Chen, Yu-Chih; Nör, Felipe et al. (2017) Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget 8:100339-100352
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Kerk, Samuel A; Finkel, Kelsey A; Pearson, Alexander T et al. (2017) 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 23:2516-2527
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Udager, A M; McHugh, J B; Goudsmit, C M et al. (2017) Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol :
Gainor, Danielle L; Marchiano, Emily; Bellile, Emily et al. (2017) Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngol Head Neck Surg 157:625-630
Nör, Felipe; Warner, Kristy A; Zhang, Zhaocheng et al. (2017) Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res 23:1036-1048

Showing the most recent 10 out of 249 publications